Medac Pharma Llp

Medac Pharma LLP from London UK is a large, holding company with an active status. Founded eight years ago in February 2017, the company employs 24 people and operates from a virtual address, registered at 2 Leman Street, London. It’s managed by two directors and has one reported owner, though this list may not be exhaustive. The company holds a 3.0 Google rating based on a single review and regularly imports pharmaceutical products—85 months of import activity were recorded, with the latest operation occurring in January 2025.

The company’s website reveals a focus on improving human health, with a mission to make the best medical treatments available worldwide. Medac Pharma LLP caters to four key medical disciplines: rheumatology, urology, haematology, and oncology. It operates as a distributor of established pharmaceutical products and diagnostics, also developing new therapies. The website also includes a section exclusively for healthcare professionals, and highlights a commitment to responsibility, integrity, and diversity. A contact number and email address are provided, alongside links to terms and conditions and a privacy policy.

Financially, Medac Pharma LLP shows a mixed picture. While the company's average number of employees increased slightly from 24 to 26, total profits decreased by 4.2% to £5.3 million. Net assets remain substantial, however, and the company’s accounts are audited, suggesting a degree of financial rigor. Bank borrowings are stable, and creditors have decreased, indicating good debt management. The company’s size—meeting two of three criteria for a large company—helps it maintain agility, but the slight dip in profits warrants attention. No auditor is specifically mentioned, which is common for companies of this size.

Registered in England/Wales under the registration number OC415849, with a registered address at E1W 9US, United Kingdom, London, 2 Leman Street.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.